Vaishali Pharma Intrinsic Value
VAISHALI Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹7.92 | ₹6.34 - ₹9.50 | +16.6% | EPS: ₹0.36, Sector P/E: 22x |
| Book Value Method | asset | ₹16.98 | ₹15.28 - ₹18.68 | +150.1% | Book Value/Share: ₹25.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹13.58 | ₹12.22 - ₹14.94 | +100.0% | Revenue/Share: ₹52.31, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹13.58 | ₹12.22 - ₹14.94 | +100.0% | EBITDA: ₹8.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹3.57 | ₹2.86 - ₹4.28 | -47.4% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹2.30 | ₹2.07 - ₹2.53 | -66.1% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹5.56 | ₹5.00 - ₹6.12 | -18.1% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹13.58 | ₹12.22 - ₹14.94 | +100.0% | ROE: 6.2%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹14.23 | ₹12.81 - ₹15.65 | +109.6% | EPS: ₹0.36, BVPS: ₹25.00 |
Want to compare with current market value? Check VAISHALI share price latest .
Valuation Comparison Chart
VAISHALI Intrinsic Value Analysis
What is the intrinsic value of VAISHALI?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Vaishali Pharma (VAISHALI) is ₹13.58 (median value). With the current market price of ₹6.79, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹2.30 to ₹16.98, indicating ₹2.30 - ₹16.98.
Is VAISHALI undervalued or overvalued?
Based on our multi-method analysis, Vaishali Pharma (VAISHALI) appears to be trading below calculated value by approximately 100.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 21.00 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.69 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 6.2% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 4.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.24x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
Related Pages for Vaishali Pharma
Additional stock information and data for VAISHALI
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-18 Cr | ₹-18 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |
| March 2021 | ₹2 Cr | ₹2 Cr | Positive Free Cash Flow | 8/10 |